AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Insight Molecular Diagnostics Inc. Director's Dealing 2018

Apr 12, 2018

34238_dirs_2018-04-12_e3366684-3347-4bda-8a0e-cb301465034c.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: OncoCyte Corp (OCX)
CIK: 0001642380
Period of Report: 2018-04-02

Reporting Person: ANDREWS RONALD ASBURY (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option to Purchase Common Stock	$2.1000	2028-04-01	Common Stock (20000)		Direct

Footnotes

F1: Will become exercisable in four equal installments at the end of each calendar quarter based upon continued service on the board of directors from the date of grant on April 2, 2018.